Dr Reddy's Laboratories Retained Earnings (Accumulated Deficit) 2010-2024 | RDY
Dr Reddy's Laboratories retained earnings (accumulated deficit) from 2010 to 2024. Retained earnings (accumulated deficit) can be defined as profits reinvested in the corporation after dividends have been paid out.
- Dr Reddy's Laboratories retained earnings (accumulated deficit) for the quarter ending June 30, 2024 were $3.351B, a 19.55% increase year-over-year.
- Dr Reddy's Laboratories retained earnings (accumulated deficit) for 2024 were $3.183B, a 21.35% increase from 2023.
- Dr Reddy's Laboratories retained earnings (accumulated deficit) for 2023 were $2.623B, a 13.26% increase from 2022.
- Dr Reddy's Laboratories retained earnings (accumulated deficit) for 2022 were $2.316B, a 8.58% increase from 2021.
Dr Reddy's Laboratories Annual Retained Earnings (Accumulated Deficit)
(Millions of US $) |
| 2024 |
$3,183 |
| 2023 |
$2,623 |
| 2022 |
$2,316 |
| 2021 |
$2,133 |
| 2020 |
$1,913 |
| 2019 |
$1,860 |
| 2018 |
$1,749 |
| 2017 |
$1,669 |
| 2016 |
$1,503 |
| 2015 |
$1,342 |
| 2014 |
$1,084 |
| 2013 |
$822 |
| 2012 |
$621 |
| 2011 |
$458 |
| 2010 |
$401 |
| 2009 |
$ |
Dr Reddy's Laboratories Quarterly Retained Earnings (Accumulated Deficit)
(Millions of US $) |
| 2024-06-30 |
$3,351 |
| 2024-03-31 |
$3,183 |
| 2023-12-31 |
$3,030 |
| 2023-09-30 |
$2,867 |
| 2023-06-30 |
$2,803 |
| 2023-03-31 |
$2,623 |
| 2022-12-31 |
$2,499 |
| 2022-09-30 |
$2,386 |
| 2022-06-30 |
$2,377 |
| 2022-03-31 |
$2,316 |
| 2021-12-31 |
$2,351 |
| 2021-09-30 |
$2,266 |
| 2021-06-30 |
$2,176 |
| 2021-03-31 |
$2,133 |
| 2020-12-31 |
$2,084 |
| 2020-09-30 |
$2,073 |
| 2020-06-30 |
$1,986 |
| 2020-03-31 |
$1,913 |
| 2019-12-31 |
$1,914 |
| 2019-09-30 |
$2,014 |
| 2019-06-30 |
$1,963 |
| 2019-03-31 |
$1,860 |
| 2018-12-31 |
$1,786 |
| 2018-09-30 |
$1,647 |
| 2018-06-30 |
$1,730 |
| 2018-03-31 |
$1,749 |
| 2017-12-31 |
$1,737 |
| 2017-09-30 |
$1,646 |
| 2017-06-30 |
$1,681 |
| 2017-03-31 |
$1,669 |
| 2016-12-31 |
$1,547 |
| 2016-09-30 |
$1,508 |
| 2016-06-30 |
$1,494 |
| 2016-03-31 |
$1,503 |
| 2015-12-31 |
$1,493 |
| 2015-09-30 |
$1,420 |
| 2015-06-30 |
$1,414 |
| 2015-03-31 |
$1,342 |
| 2014-12-31 |
$1,245 |
| 2014-09-30 |
$1,174 |
| 2014-06-30 |
$1,175 |
| 2014-03-31 |
$1,084 |
| 2013-12-31 |
$935 |
| 2013-09-30 |
$830 |
| 2013-06-30 |
$810 |
| 2013-03-31 |
$822 |
| 2012-12-31 |
$727 |
| 2012-09-30 |
$675 |
| 2012-06-30 |
$625 |
| 2012-03-31 |
$621 |
| 2011-12-31 |
$536 |
| 2011-09-30 |
$478 |
| 2011-06-30 |
$511 |
| 2011-03-31 |
$458 |
| 2010-12-31 |
$513 |
| 2010-09-30 |
$435 |
| 2010-06-30 |
$434 |
| 2010-03-31 |
$401 |
| 2009-12-31 |
$353 |
| 2009-09-30 |
$449 |
| 2009-06-30 |
$435 |
| 2009-03-31 |
$360 |
| Sector |
Industry |
Market Cap |
Revenue |
| Medical |
Medical - Generic Drugs |
$12.329B |
$3.350B |
|
Dr. Reddy's Laboratories Ltd. is an integrated global pharmaceutical company engaged in providing affordable and innovative medicines since 1984. The company markets its products in countries like the U.S., the UK, Germany, India, Russia, Venezuela, Romania and South Africa. Dr. Reddy's operates through three segments: Global Generics comprising unbranded prescription drugs along with over-the-counter drugs. It includes the operations of the company's biologics business. Pharmaceutical Services & Active Ingredients (PSAI) comprising active pharmaceutical ingredients (API) and custom pharmaceutical services. Proprietary Products and Others involving the new chemical entities, the differentiated formulations business and a dermatology specialty business. The company has a strategic partnership with Glaxo to market selected products across emerging markets outside India.
|
